当前位置:Public Access >页面
Chinese/English
The Efficacy and Safety of Fruquintinib Combined with Hepatic Arterial Infusion of Leucovorin for the Treatment of Refractory Colorectal Cancer Liver Metastases: An Open-Label, Single-Arm, Single-Center, Phase II Clinical Study

ChiCTR注册号:

Reg No. in ChiCTR:

在注册审核中,暂无注册号

研究题目:

The Efficacy and Safety of Fruquintinib Combined with Hepatic Arterial Infusion of Leucovorin for the Treatment of Refractory Colorectal Cancer Liver Metastases: An Open-Label, Single-Arm, Single-Center, Phase II Clinical Study

Study title:

The Efficacy and Safety of Fruquintinib Combined with Hepatic Arterial Infusion of Leucovorin for the Treatment of Refractory Colorectal Cancer Liver Metastases: An Open-Label, Single-Arm, Single-Center, Phase II Clinical Study

 注册状况:

 Registration:

True

注册机构:

中国临床试验注册中心(ChiCTR)

Name of the Registry:

Chinese Clinical Trial Registry (ChiCTR)

项目负责人:

中国临床试验注册中心(ChiCTR)

Corresponding person:

Chinese Clinical Trial Registry (ChiCTR)

电话:

Telephone:

13960986882

电子邮件

Email

13960986882@163.com

通讯地址:

福建省肿瘤医院腹部肿瘤内科

Address:

福建省福州市晋安区福马路420号

邮政编码

Postcode

350014

项目负责人所有单位:

福建省肿瘤医院

Institution:

Fujian Provincial Cancer Hospital

批准本研究的伦理委员会名称:

福建省肿瘤医院伦理委员会

Name of the ethic committee:

Ethics Committee of Fujian Provincial Cancer Hospi

研究疾病:

结直肠癌肝转移

Study Ailment:

Colorectal Cancer with Liver Metastasis

研究所处阶段:

Study phase:

Premarket

研究类型:

Type of Study:

Therapy Study

研究团队:

Research team:

研究实施地点:

Site of Study:

国家(地区):

中国

省(直辖市):

福建省

市(区县):

Country/Area:

CHINA

Province:

FUJIAN

City:

单位 福建省肿瘤医院
Institution Fujian Provincial Cancer Hospital

预计起止时间:

Planned Duration:

2024/7/1 0:00:00-2027/6/30 0:00:00